

BusinessSpectator

NEWS

5:53 PM, 10 Aug 2009

BioPharmica buys anti-cancer project

Source: News Bites

BioPharmica Ltd has signed a new agreement with the University of Western Australia (UWA) to own 100% of the intellectual property of the anti-cancer therapeutic HLS5 Collaborative Research and Technology project and its derivatives.

The company will provide UWA with a royalty upon the project's commercialisation.

BioPharmica has appointed Dr Robin Scaife as lead scientist for the project, and to head the company's laboratory at the Western Australian Institute for Medical Research.

BioPharmica said the commercially targeted projects resulting from a four year on-the-go research include a possible new anti-cancer therapeutic and a new anticancer strategy. The company said that clinically approved anti-mitotic drugs attracted \$US1 billion revenue per year and was sought by most pharmaceutical companies.

STOCK DASHBOARD: August 10, 2009

BioPharmica

Last traded August 07, 2009: 2.60c

Price change from previous trading day: -3.7%

Relative Strength (6 months percentile rank): 57.7

Market capitalisation: \$1.9 million

Turnover volume: 132,300.0

Volume Index (1 is average): 5.8

Turnover value: \$3,690

Turnover period: 12 years 11 months

Value of \$1,000 invested 1 year ago: \$578

Source: www.BuySellTips.com

